- Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial CNBC
- Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing Intellia Therapeutics
- Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 Yahoo Finance
- Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial statnews.com
- Intellia Therapeutics Initiates Rolling Submission of GlobeNewswire
Add Comment